Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,531 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04262375 | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION(DOMINATION) | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT04262388 | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation(DOME) | withdrawn | Phase 2 |
| 0 |
| University Health Network, TorontoOTHER |
| 1 |
| Nov 17, 2020 |
| clinicaltrials |
| NCT02109653 | Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC | withdrawn | Phase 2 | 0 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT01925378 | A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center, HoustonOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03699033 | Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Stephanie SmiddyOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | withdrawn | Phase 2 | 0 | Alain AlgaziOTHER | 0 | Oct 26, 2020 | clinicaltrials |
| NCT04116359 | Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT00226746 | Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer | withdrawn | Phase 2 | 0 | New York Presbyterian Brooklyn Methodist HospitalOTHER | 1 | Sep 18, 2020 | clinicaltrials |
| NCT03628144 | Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT04093115 | Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | withdrawn | Phase 2 | 0 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 3, 2020 | clinicaltrials |
| NCT03598816 | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma(PIVOT-RCC) | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Aug 13, 2020 | clinicaltrials |
| NCT01859689 | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 27, 2020 | clinicaltrials |
| NCT04149444 | A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer(TACTIC) | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT02831491 | A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 0 | Jun 9, 2020 | clinicaltrials |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT00367718 | Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma | withdrawn | Phase 2 | 0 | Johns Hopkins UniversityOTHER | 2 | May 18, 2020 | clinicaltrials |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | HealthPartners InstituteOTHER | 0 | May 7, 2020 | clinicaltrials |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT04025567 | Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 16, 2020 | clinicaltrials |
| NCT04058964 | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2020 | clinicaltrials |
| NCT02487849 | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma(HIPEC) | withdrawn | Phase 2 | 0 | Krankenhaus Barmherzige Schwestern LinzOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT02580253 | Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02289300 | A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients | withdrawn | Phase 2 | 0 | A2 Healthcare Taiwan CorporationINDUSTRY | 1 | Jan 13, 2020 | clinicaltrials |
| NCT04044651 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection | withdrawn | Phase 2 / Phase 3 | 0 | Shi MingOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01913691 | Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 17, 2019 | clinicaltrials |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT03185871 | Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses | withdrawn | Phase 2 | 0 | University of Wisconsin, MadisonOTHER | 0 | Nov 15, 2019 | clinicaltrials |
| NCT02538432 | Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors | withdrawn | Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT03311672 | T-Cell PET Imaging With [18F]F-AraG in Lung Cancer | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 0 | Oct 21, 2019 | clinicaltrials |
| NCT02030184 | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas | withdrawn | Phase 1 / Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT04130399 | Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT02885727 | Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)(Panc-Durval+RT) | withdrawn | Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 0 | Sep 12, 2019 | clinicaltrials |
| NCT02466568 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT02946138 | Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Sep 9, 2019 | clinicaltrials |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT03778879 | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B | withdrawn | Phase 1 / Phase 2 | 0 | Alan KatzOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | withdrawn | Phase 1 / Phase 2 | 0 | William Grosh, MDOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT03836157 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | withdrawn | Phase 2 | 0 | University of OklahomaOTHER | 1 | Jun 27, 2019 | clinicaltrials |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Hitendra PatelOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT02527772 | Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma(LD-FOX4/HCC) | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02534337 | Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02584556 | Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02585479 | Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Nov 17, 2020source: clinicaltrials